Literature DB >> 22914844

The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?

Rémy Phan-Ba1, Shibeshih Belachew, Olivier Outteryck, Gustave Moonen, Christian Sindic, Mathieu Vokaer, Patrick Vermersch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22914844     DOI： 10.1212/WNL.0b013e31826846b4

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

Review 1.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

2.  Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Authors:  Martijn T Wijburg; Iris Kleerekooper; Birgit I Lissenberg-Witte; Marlieke de Vos; Clemens Warnke; Bernard M J Uitdehaag; Frederik Barkhof; Joep Killestein; Mike P Wattjes
Journal:  JAMA Neurol       Date:  2018-07-01       Impact factor: 18.302

Review 3.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

4.  Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.

Authors:  Luca Prosperini; Nicola de Rossi; Cristina Scarpazza; Lucia Moiola; Mirco Cosottini; Simonetta Gerevini; Ruggero Capra
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

5.  Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.

Authors:  Stefania Federica De Mercanti; Dario Gned; Manuela Matta; Marco Iudicello; Emanuele Franchin; Marinella Clerico
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

6.  Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Hans Lindå; Anders von Heijne
Journal:  Front Neurol       Date:  2013-02-18       Impact factor: 4.003

7.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Authors:  Tuan Dong-Si; Sandra Richman; Mike P Wattjes; Made Wenten; Sarah Gheuens; Jeffrey Philip; Shoibal Datta; James McIninch; Carmen Bozic; Gary Bloomgren; Nancy Richert
Journal:  Ann Clin Transl Neurol       Date:  2014-10-09       Impact factor: 4.511

Review 8.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

Review 9.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.